跳至主要内容
临床试验/NCT00001990
NCT00001990已完成不适用

An Open-Label, Uncontrolled Clinical Trial of Oral 566C80 for the Treatment of Patients With Severe PCP Who Are Intolerant and/or Unresponsive to Therapy With Trimethoprim/Sulfamethoxazole and Parenteral Pentamidine

Glaxo Wellcome1 个研究点 分布在 1 个国家开始时间: 2001年8月31日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
试验地点
1

研究概览

简要总结

To facilitate provision of atovaquone (566C80) to patients who have severe Pneumocystis carinii pneumonia (PCP) and are intolerant and/or unresponsive to trimethoprim / sulfamethoxazole ( TMX / SMX ); to monitor serious adverse events attributable to 566C80.

研究设计

研究类型
Interventional
主要目的
Treatment
盲法
None

入排标准

年龄范围
1 Day 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Patients must have the following:
  • •Clinical diagnosis of acute severe Pneumocystis carinii pneumonia (PCP).
  • •Dose-limiting intolerance to TMP / SMX and parenteral pentamidine.
  • •Willingness and ability to give informed consent.

排除标准

  • •Co-existing Condition:
  • •Patients with a history of intolerance to 566C
  • •Patients with the following prior conditions are excluded: History of serious dose-limiting adverse experience during previous 566C80 therapy, thought to be attributable to the drug.
  • •Trimethoprim / sulfamethoxazole (TMP/SMX); pentamidine.

研究者

发起方
Glaxo Wellcome
申办方类型
Industry

研究点 (1)

Loading locations...

相似试验